Quarterly report · Q3
4548.TEDINET S100Q6VH
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥34.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥28.1bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥3.4bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥6.2bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.9bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥4.2bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.9bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.4bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.6bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥5.4bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥76.6bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥75.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥76.3bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥6.9bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥8.9bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥69.8bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥66.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥67.9bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥22.0bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥21.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥65.42 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.88 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.32 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥95.25 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥6.14 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 91.0% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.0% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E00970-000LALreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.0bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥18.0bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥18.0bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.4bn |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥26.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥26.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥3.4bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥6.7bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥6.7bn |
| jpcrp040300-q3r_E00970-000LALreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥1.9bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥21.4bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥21.4bn |
| jpcrp040300-q3r_E00970-000Pharmaceuticalreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥4.4bn |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥28.1bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥28.1bn |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥6.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 387
| Item | Context | Value | Unit |
|---|---|---|---|
| Asset retirement obligations ncl | Prior1YearInstant | 36000000 | JPY |
| Asset retirement obligations ncl | CurrentQuarterInstant | 36000000 | JPY |
| Other ncl | Prior1YearInstant | 106000000 | JPY |
| Other ncl | CurrentQuarterInstant | 106000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 1370000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 1452000000 | JPY |
| Liabilities | Prior1YearInstant | 8904000000 | JPY |
| Liabilities | CurrentQuarterInstant | 6869000000 | JPY |
| Capital stock | Prior1YearInstant | 3840000000 | JPY |
| Capital stock | CurrentQuarterInstant | 3840000000 | JPY |
| Capital surplus | Prior1YearInstant | 5301000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 5301000000 | JPY |
| Retained earnings | Prior1YearInstant | 53305000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 55367000000 | JPY |
| Treasury stock | Prior1YearInstant | -802000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -2279000000 | JPY |
| Shareholders equity | Prior1YearInstant | 61645000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 62229000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 3212000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 2913000000 | JPY |
| Deferred gains or losses on hedges | Prior1YearInstant | -102000000 | JPY |
| Deferred gains or losses on hedges | CurrentQuarterInstant | -15000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 1251000000 | JPY |
| Foreign currency translation adjustment | CurrentQuarterInstant | 4235000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 333000000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 404000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 4694000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 7537000000 | JPY |
| Net assets | Prior1YearInstant | 66340000000 | JPY |
| Net assets | CurrentQuarterInstant | 69767000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 75244000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 76636000000 | JPY |
| Net sales | Prior1YTDDuration | 28145000000 | JPY |
| Net sales | CurrentYTDDuration | 26162000000 | JPY |
| Cost of sales | Prior1YTDDuration | 10998000000 | JPY |
| Cost of sales | CurrentYTDDuration | 11552000000 | JPY |
| Gross profit | Prior1YTDDuration | 17147000000 | JPY |
| Gross profit | CurrentYTDDuration | 14610000000 | JPY |
| Personal expenses sga | Prior1YTDDuration | 2069000000 | JPY |
| Personal expenses sga | CurrentYTDDuration | 2281000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 87000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 88000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 75000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 86000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 5855000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 5355000000 | JPY |
| Other sga | Prior1YTDDuration | 2824000000 | JPY |
| Other sga | CurrentYTDDuration | 3392000000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 10913000000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 11203000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |